Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 10;13:277–289. doi: 10.2147/OTT.S235940

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Su et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Schema of the predicted mechanisms implicated in SW480 and HT29 cells response to cisplatin and miR-519d. MiR-519d inhibits TRIM32 expression and thus suppresses the expression of Bcl-2 and promotes the cisplatin-caused generation of ROS. Because of the high level of ROS and inhibition of Bcl-2, apoptosis signals produced by cisplatin were expanded to trigger the mitochondria-mediated intrinsic apoptosis pathway. As a result, MMP (Δφ) was decreased and the effector caspases (caspase-9 and caspase-3) are triggered to cause the apoptotic cell death of SW480 and HT29 cells.

Abbreviations: TRIM32, tripartite motif 32; Bcl-2, B-cell lymphoma-2; MMP, mitochondrial membrane potential, ROS, reactive oxygen species.